arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Myriad Genetics, Inc.

MYGN Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances
$5.76
▲ +4.0% Today
as of Oct 22, 16:50 ET
Last 30 days +51.98% Sep 14 → Oct 22
$3.63 $4.20 $4.78 $5.35 $5.92 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$5.57
High
$5.92
Low
$5.39
Volume
$4M
Avg Vol
$2M
Mkt Cap
$409M
P/E (TTM)
—
Beta
—
52w High
$8.50
52w Low
$2.74
Div Yield
—
Shares Out
$96M

Recent Press Releases & News last 60 days · 25 items

Oct 22 · 14:17 MT Newswires
Myriad Genetics Says New Results Show Potential of MRD Detection in Colorectal, Pancreatic Cancers
Oct 22 · 13:11 Simply Wall St.
Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions
Oct 22 · 13:05 PR GlobeNewswire
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
▸ Show all 25 press releases & news Free account →

MYGN earnings at a glance

Myriad Genetics, Inc. (MYGN) is scheduled to report earnings on Monday, November 2, 2026 — in 10 days. Analysts expect earnings per share of -$0.24, compared with -$0.13 in the same quarter last year (-85%). The options market is pricing a move of about ±5.8% after the report, a range of roughly $5.42 to $6.10 from today's $5.76. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±29.2% on average; after the most recent report on Jul 30, 2026 it moved -46.7%. That means options currently expect less movement than MYGN has typically delivered. MYGN beat the consensus EPS estimate in 3 of its last 6 reported quarters. Implied volatility is currently 47%. The share price of $5.76 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.74
$8.50
52% of range
Avg surprise (last 6)
-24.9%
Avg reaction (last 6)
-13.3%
33% positive
Latest IV / EM
47%
EM ±5.8% · $4 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.42$-1.06$-0.70$-0.34$0.02 Actual $-0.67Actual $-1.42Actual $-0.75Actual $-0.29Actual $-0.41Actual $-0.24Actual $-0.14Est $-0.17Actual $-0.06Est $-0.11Actual $-0.13Est $-0.11Actual $0.02Est $-0.11Actual $-0.16Est $-0.16Actual $-0.33Est $-0.08 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-330M$-192M$-53M$85M$224M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 30, 2026Jun/2026 $-0.33 $-0.08 -312.5% -33.3% -46.7% earnings
Tue May 5, 2026Mar/2026 $-0.16 $-0.16 0.0% -14.3% -18.3% earnings
Mon Feb 23, 20268K 2026-02-23 $0.02 $-0.11 +118.2% — +1.1% earnings
Mon Nov 3, 2025Sep/2025 $-0.13 $-0.11 -18.2% — -21.0% earnings
Tue Aug 5, 2025Jun/2025 $-0.06 $-0.11 +45.5% — +46.5% earnings
Tue May 6, 2025Mar/2025 $-0.14 $-0.17 +17.6% — -41.3% earnings
Mon Sep 30, 2024Sep 2024 $-0.24 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.41 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.29 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.75 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.42 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.67 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Mon Nov 2, 2026Sep/2026OTHER -$0.24-$0.13 -84.6%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$191M$200M—$206M$213M$196M—$213M
Cost of revenue$64M$63M—$62M$61M$62M—$64M
Gross profit$127M$138M—$144M$152M$134M—$150M
Operating income$-39M$-31M—$-23M$-329M$-29M—$-20M
Net income$-43M$-34M—$-27M$-330M$-100,000—$-22M
EPS (diluted)$-0.46$-0.36—$-0.29$-3.57——$-0.24

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$115M$124M$150M$145M$74M$92M$102M$100M
Inventory$31M$28M$31M$32M$29M$28M$28M$26M
Total current assets$289M$313M$333M$345M$284M$287M$298M$293M
Total assets$639M$674M$707M$728M$677M$1.01B$1.03B$1.08B
Long-term debt$121M$120M$120M$120M$0$59M$40M$39M
Total liabilities$335M$336M$339M$355M$289M$301M$326M$350M
Total equity$304M$337M$368M$373M$388M$705M$701M$732M

Implied volatility — last 90 days

46%151%256%361%466% Jun 07 — IV 158% · EM ±21.9%Jun 08 — IV 233% · EM ±30.8%Jun 12 — IV 260% · EM ±26.6%Jun 19 — IV 82% · EM ±18.2%Jun 22 — IV 144% · EM ±30.1%Jun 23 — IV 158% · EM ±32.4%Jun 24 — IV 57% · EM ±11.5%Jun 25 — IV 145% · EM ±28.4%Jun 26 — IV 92% · EM ±17.6%Jun 29 — IV 109% · EM ±19.2%Jul 06 — IV 99% · EM ±13.7%Jul 09 — IV 90% · EM ±10.7%Jul 13 — IV 112% · EM ±9.4%Jul 14 — IV 114% · EM ±8.3%Jul 15 — IV 136% · EM ±8.0%Jul 21 — IV 115% · EM ±26.6%Jul 22 — IV 97% · EM ±22.1%Jul 23 — IV 148% · EM ±33.3%Jul 24 — IV 60% · EM ±13.4%Jul 27 — IV 145% · EM ±30.3%Jul 28 — IV 220% · EM ±45.1%Jul 29 — IV 79% · EM ±15.9%Jul 30 — IV 356% · EM ±69.7%Jul 31 — IV 59% · EM ±11.3%Aug 03 — IV 75% · EM ±13.2%Aug 04 — IV 101% · EM ±17.4%Aug 06 — IV 467% · EM ±75.5%Aug 20 — IV 335% · EM ±14.0%Aug 24 — IV 149% · EM ±31.1%Aug 25 — IV 215% · EM ±43.9%Aug 26 — IV 120% · EM ±24.0%Aug 27 — IV 120% · EM ±23.6%Aug 28 — IV 132% · EM ±25.3%Aug 31 — IV 131% · EM ±23.3%Sep 01 — IV 114% · EM ±19.7%Sep 02 — IV 139% · EM ±23.2%Sep 03 — IV 144% · EM ±23.2%Sep 04 — IV 150% · EM ±23.4%Sep 07 — IV 170% · EM ±23.5%Sep 08 — IV 179% · EM ±23.6%Sep 09 — IV 189% · EM ±23.7%Sep 10 — IV 202% · EM ±23.8%Sep 11 — IV 397% · EM ±43.9%Sep 15 — IV 53% · EM ±3.9%Sep 17 — IV 191% · EM ±8.0%Sep 21 — IV 90% · EM ±18.7%Sep 24 — IV 86% · EM ±16.9%Sep 25 — IV 100% · EM ±19.2%Sep 29 — IV 158% · EM ±27.2%Sep 30 — IV 159% · EM ±26.6%Oct 02 — IV 113% · EM ±17.6%Oct 07 — IV 47% · EM ±5.8%

Sector peers

TKNO
Alpha Teknova, Inc.
$468M $6.15-16.8%
IMDX
Insight Molecular Diagnostics Inc.
$114M $2.84-6.3%
ICCC
ImmuCell Corporation
$87M $10.44-0.1%
ACHV
Achieve Life Sciences, Inc.
$745M $6.50-0.1%
QCLS
Q/C Technologies, Inc.
$19M $0.53+6.0%
VNRX
VolitionRX Limited
$7M $0.17-0.5%

MYGN earnings FAQ

When is MYGN's next earnings date?

Myriad Genetics, Inc. is expected to report on November 2, 2026.

What is MYGN's expected move for earnings?

Options currently price a move of about ±5.8%, or $0.34 per share either way from $5.76.

How does MYGN stock usually react to earnings?

Across the last 6 reports the average next-day move was ±29.2%, up 2 times and down 4 times.

What EPS are analysts expecting from Myriad Genetics, Inc.?

The consensus estimate is -$0.24 per share, versus -$0.13 a year ago.

What is MYGN's implied volatility?

MYGN's at-the-money implied volatility is about 47% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in